-
Product Insights
New![]()
Net Present Value Model: Adaptimmune Therapeutics Plc’s AFP
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADPA-2AFP in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADPA-2AFP in Hepatocellular Carcinoma Drug Details: ADPA-2AFP is under development for the treatment of hepatocellular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADPA-2AFP in Hepatocellular Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADPA-2AFP in Hepatocellular Carcinoma Drug Details: ADPA-2AFP is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACT-101 in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ACT-101 in Ulcerative Colitis Drug Details:ACT-101 is under development for the treatment of myasthenia gravis, multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACT-101 in Hashimoto Thyroiditis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ACT-101 in Hashimoto ThyroiditisDrug Details:ACT-101 is under development for the treatment of myasthenia gravis, multiple sclerosis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Bladder Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Gallbladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Gallbladder Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Squamous Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Squamous Non-Small Cell Lung Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Urethral Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.